Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential value of $3 million, supports development of the company’s aerosolized KL4 surfactant as a treatment for radiation-induced lung injury.
In July 2015, the company received a second $1 million supplement from the grant. The initial award was $0.6 million. According to the company, initial pre-clinical research funded by the grant shows that the aerosolized KL4 surfactant administered after radiation-induced lung injury showed positive effects both when given early and later after the injury.
In March 2015, the company restructured to focus on development of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. A Phase 2b trial of Aerosurf for that indication began in December 2015.
Read the Windtree Therapeutics press release.
